Subscribe To
TSVT / 2seventy bio A Buy For Abecma And CAR T Platform
TSVT News
By Zacks Investment Research
September 13, 2023
2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal
2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collab more_horizontal
By Reuters
September 12, 2023
2seventy bio to lay off 40% of workforce
2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma. more_horizontal
By Seeking Alpha
June 21, 2023
2seventy bio: Nothing Properly Explains The Low Valuation
2seventy bio: Nothing Properly Explains The Low Valuation more_horizontal
By Zacks Investment Research
June 15, 2023
2seventy (TSVT) Down 9% on Patient Death in Leukemia Study
Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is st more_horizontal
By Seeking Alpha
May 6, 2023
2seventy bio, Inc. (TSVT) Q1 2023 Earnings Call Transcript
2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ET Company Participants Jenn Snyder - SVP of Corporate Affairs more_horizontal
By Zacks Investment Research
May 3, 2023
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to l more_horizontal
By Business Wire
May 2, 2023
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation more_horizontal
By Zacks Investment Research
March 16, 2023
2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the nu more_horizontal